100
Participants
Start Date
November 14, 2024
Primary Completion Date
September 1, 2025
Study Completion Date
September 1, 2025
Fluid challenge (cristalloids) OR passive leg raising
"Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition"
RECRUITING
Hôpital Lariboisière - APHP, Paris
RECRUITING
Hôpital européen Georges Pompidou - APHP, Paris
NOT_YET_RECRUITING
CHU de Limoges, Limoges
Collaborators (1)
Philips Healthcare
INDUSTRY
UltraSight
INDUSTRY
Assistance Publique - Hôpitaux de Paris
OTHER